eligibility_summary
Eligible: patients with unresectable/metastatic colorectal, biliary tract, or gastroesophageal cancer, or HCC not amenable to locoregional therapy, must have prior therapy and be recovered from prior treatment side effects. Exclude: history/current/suspected ILD/pneumonitis, severe respiratory compromise, leptomeningeal disease, significant corneal, cardiovascular, or cerebrovascular disease, uncontrolled systemic infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Patritumab deruxtecan (MK-1022, HER3-DXd, U3-1402), a biologic antibody–drug conjugate consisting of patritumab (human anti-HER3 monoclonal antibody) linked via a cleavable linker to the deruxtecan payload (a potent topoisomerase I inhibitor). Mechanism of action: the antibody binds HER3 (ERBB3) on tumor cells, is internalized, and releases DXd intracellularly to inhibit Topo I, causing DNA damage and cell death, the membrane-permeable payload can produce a bystander effect. Cells/pathways targeted: HER3-expressing gastrointestinal cancer cells (colorectal, biliary tract, hepatocellular, gastroesophageal), downregulates HER3-driven ErbB signaling (PI3K/AKT, MAPK) while directly targeting DNA replication machinery via Topo I inhibition. Administered IV every 3 weeks.